Shire PLC (SHPG) Position Trimmed by MUFG Americas Holdings Corp

MUFG Americas Holdings Corp lowered its stake in Shire PLC (NASDAQ:SHPG) by 21.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,087 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. MUFG Americas Holdings Corp’s holdings in Shire were worth $560,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Centaurus Financial Inc. bought a new stake in shares of Shire during the 2nd quarter valued at $102,000. Rehmann Capital Advisory Group boosted its holdings in shares of Shire by 226.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 472 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Shire during the 2nd quarter valued at $129,000. TRUE Private Wealth Advisors bought a new stake in shares of Shire during the 3rd quarter valued at $148,000. Finally, Whitener Capital Management Inc. bought a new stake in shares of Shire during the 3rd quarter valued at $156,000. Institutional investors and hedge funds own 20.49% of the company’s stock.

SHPG opened at $174.95 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $53.41 billion, a PE ratio of 11.39, a P/E/G ratio of 1.58 and a beta of 1.01. Shire PLC has a 1 year low of $123.73 and a 1 year high of $182.47.

Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.65 by ($0.01). The company had revenue of $3.87 billion during the quarter. Shire had a return on equity of 12.70% and a net margin of 30.63%. Shire’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.81 earnings per share. Sell-side analysts forecast that Shire PLC will post 15.09 earnings per share for the current fiscal year.

A number of brokerages have recently commented on SHPG. SunTrust Banks cut shares of Shire from a “buy” rating to a “hold” rating in a report on Tuesday, December 11th. ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a report on Thursday, December 6th. B. Riley restated a “buy” rating on shares of Shire in a report on Tuesday, December 4th. BidaskClub cut shares of Shire from a “buy” rating to a “hold” rating in a report on Friday, November 30th. Finally, Zacks Investment Research restated a “hold” rating on shares of Shire in a report on Thursday, November 15th. Ten research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $201.11.

COPYRIGHT VIOLATION WARNING: This report was originally published by WKRB News and is the property of of WKRB News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.wkrb13.com/2018/12/16/shire-plc-shpg-position-trimmed-by-mufg-americas-holdings-corp.html.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Further Reading: SEC Filing

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply